GLP-1 Medicines 2.0: Nature Medicine-Feb. 26

Glucagon-like peptide-1 (GLP-1) receptor agonists have evolved from glucose-lowering agents for type 2 diabetes into transformative therapies reshaping cardiometabolic medicine. In this comprehensive review, Daniel Drucker outlines how GLP-1–based therapies now extend well beyond glycemic control, influencing obesity, cardiovascular disease, peripheral artery disease, obstructive sleep apnea, and potentially multiple non-metabolic disorders.

These agents exert benefits through several complementary mechanisms: sustained weight reduction, improved insulin sensitivity, attenuation of systemic inflammation, and direct receptor-mediated effects in diverse tissues. The development of long-acting formulations with optimised pharmacokinetics has amplified weight loss and cardiometabolic benefits. Furthermore, next-generation multi-agonist molecules incorporating additional peptide epitopes (e.g., dual or triple incretin-based constructs) are demonstrating enhanced metabolic efficacy.

Importantly, research is expanding into novel indications, including metabolic liver disease, neurodegenerative disorders, substance use disorders, inflammatory bowel disease, arthritis, and even type 1 diabetes. These developments reflect a paradigm shift—from symptom control to disease modification.

However, critical questions remain regarding long-term safety, durability of benefit, comparative effectiveness among agents, access inequities, and economic sustainability.

In summary, GLP-1 medicines are no longer simply antidiabetic drugs; they represent a rapidly expanding therapeutic platform with multisystem implications. The next decade will determine whether these agents achieve their full potential as cornerstone therapies in metabolic and inflammatory disease management.